PMID- 30386680
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240403
IS  - 2162-4011 (Print)
IS  - 2162-402X (Electronic)
IS  - 2162-4011 (Linking)
VI  - 7
IP  - 10
DP  - 2018
TI  - CD40L coding oncolytic adenovirus allows long-term survival of humanized mice 
      receiving dendritic cell therapy.
PG  - e1490856
LID - 10.1080/2162402X.2018.1490856 [doi]
LID - e1490856
AB  - Dendritic cells (DCs) are crucial players in promoting immune responses. 
      Logically, adoptive DC therapy is a promising approach in cancer immunotherapy. 
      One of the major obstacles in cancer immunotherapy in general is the 
      immunosuppressive tumor microenvironment, which hampers the maturation and 
      activation of DCs. Therefore, human clinical outcomes with DC therapy alone have 
      been disappointing. In this study, we use fully serotype 3 oncolytic adenovirus 
      Ad3-hTERT-CMV-hCD40L, expressing human CD40L, to modulate the tumor 
      microenvironment with subsequently improved function of DCs. We evaluated the 
      synergistic effects of Ad3-hTERT-CMV-hCD40L and DCs in the presence of human 
      peripheral blood mononuclear cells ex vivo and in vivo. Tumors treated with 
      Ad3-hTERT-CMV-hCD40L and DCs featured greater antitumor effect compared with 
      unarmed virus or either treatment alone. 100% of humanized mice survived to the 
      end of the experiment, while mice in all other groups died by day 88. Moreover, 
      adenovirally-delivered CD40L induced activation of DCs, leading to induction of 
      Th1 immune responses. These results support clinical trials with 
      Ad3-hTERT-CMV-hCD40L in patients receiving DC therapy.
FAU - Zafar, Sadia
AU  - Zafar S
AD  - Cancer Gene Therapy Group, University of Helsinki, Helsinki, Finland.
FAU - Sorsa, Suvi
AU  - Sorsa S
AD  - Cancer Gene Therapy Group, University of Helsinki, Helsinki, Finland.
AD  - TILT Biotherapeutics Ltd, Helsinki, Finland.
FAU - Siurala, Mikko
AU  - Siurala M
AD  - Cancer Gene Therapy Group, University of Helsinki, Helsinki, Finland.
AD  - TILT Biotherapeutics Ltd, Helsinki, Finland.
FAU - Hemminki, Otto
AU  - Hemminki O
AD  - Cancer Gene Therapy Group, University of Helsinki, Helsinki, Finland.
AD  - Division of Urology, Helsinki University Hospital Comprehensive Cancer Center, 
      Helsinki, Finland.
FAU - Havunen, Riikka
AU  - Havunen R
AD  - Cancer Gene Therapy Group, University of Helsinki, Helsinki, Finland.
AD  - TILT Biotherapeutics Ltd, Helsinki, Finland.
FAU - Cervera-Carrascon, Victor
AU  - Cervera-Carrascon V
AUID- ORCID: 0000-0001-6684-3666
AD  - Cancer Gene Therapy Group, University of Helsinki, Helsinki, Finland.
AD  - TILT Biotherapeutics Ltd, Helsinki, Finland.
FAU - Santos, Joao Manuel
AU  - Santos JM
AD  - Cancer Gene Therapy Group, University of Helsinki, Helsinki, Finland.
AD  - TILT Biotherapeutics Ltd, Helsinki, Finland.
FAU - Wang, Hongjie
AU  - Wang H
AD  - Department of Pathology, University of Washington, Seattle, WA, USA.
FAU - Lieber, Andre
AU  - Lieber A
AD  - Department of Pathology, University of Washington, Seattle, WA, USA.
FAU - De Gruijl, Tanja
AU  - De Gruijl T
AD  - Department of Medical Oncology, VU University Medical Center, Amsterdam, the 
      Netherlands.
FAU - Kanerva, Anna
AU  - Kanerva A
AD  - Cancer Gene Therapy Group, University of Helsinki, Helsinki, Finland.
AD  - Department of Obstetrics and Gynecology, Helsinki University Central Hospital, 
      Helsinki, Finland.
FAU - Hemminki, Akseli
AU  - Hemminki A
AD  - Cancer Gene Therapy Group, University of Helsinki, Helsinki, Finland.
AD  - TILT Biotherapeutics Ltd, Helsinki, Finland.
AD  - Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180815
PL  - United States
TA  - Oncoimmunology
JT  - Oncoimmunology
JID - 101570526
PMC - PMC6207416
OTO - NOTNLM
OT  - Ad3
OT  - CD40L
OT  - Dendritic cells
OT  - T-cells
OT  - oncolytic adenovirus
EDAT- 2018/11/06 06:00
MHDA- 2018/11/06 06:01
PMCR- 2019/08/15
CRDT- 2018/11/03 06:00
PHST- 2018/04/30 00:00 [received]
PHST- 2018/06/13 00:00 [revised]
PHST- 2018/06/13 00:00 [accepted]
PHST- 2018/11/03 06:00 [entrez]
PHST- 2018/11/06 06:00 [pubmed]
PHST- 2018/11/06 06:01 [medline]
PHST- 2019/08/15 00:00 [pmc-release]
AID - 1490856 [pii]
AID - 10.1080/2162402X.2018.1490856 [doi]
PST - epublish
SO  - Oncoimmunology. 2018 Aug 15;7(10):e1490856. doi: 10.1080/2162402X.2018.1490856. 
      eCollection 2018.